Cell Therapeutics, Inc. (CTI) To Expand Sales Force in Europe
Move Intended to Provide Critical Mass and Accelerated Opportunity to Expand Sales of TRISENOX in Europe
"We saw this as a perfect opportunity for CTI-Europe. For the past two years PharmaMar made a significant financial investment not only in training an oncology sales force but also in identifying the physicians who treat the majority of patients with blood-related cancers in each of the major market countries in Europe where their field force was based," noted James A. Bianco, M.D., President and CEO of CTI. "We believe we can leverage PharmaMar's investment and significantly expand sales of TRISENOX in Europe."
"Within the next several weeks we expect to have approximately 16 fully trained field-based country managers and sales representatives in eight major market countries selling TRISENOX," noted Steve Aselage, CTI's Executive Vice President of Global Commercial Operations. "This experienced sales force will be useful in promoting additional commercial products, which we are actively seeking to acquire. This should be an exciting year for the global commercial team and a year of revenue growth for TRISENOX."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.